VEGFA and age-related macular degeneration: Moreover, even after adjusting for anti-VEGF treatment protocol as a covariate, correlations between the time from exudative AMD diagnosis to the initiation of bevacizumab therapy in regard to CSMT and BCVA remained nonsignificant after intravitreal bevacizumab induction phase (R = 0.019, p = 0.840 and R = 0.030, p = 0.767, Table 4, respectively), at 1 year (R = 0.071, p = 0.425 and R = 0.005, p = 0.997, Table 4, respectively) and at 2 years (R = 0.069, p = 0.426 and R = 0.034, p = 0.643, Table 4, respectively).